Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketamine + butorphanol is a combination of two pharmaceutical agents used primarily in veterinary medicine for sedation, anesthesia induction, and analgesia. Ketamine is a dissociative anesthetic that acts as an NMDA receptor antagonist, producing profound analgesia and anesthesia with minimal respiratory depression. Butorphanol is an opioid analgesic with mixed agonist-antagonist activity; it acts as a partial agonist at the mu-opioid receptor and a full agonist at the kappa-opioid receptor, providing both analgesic and sedative effects. This combination is commonly used for chemical immobilization of animals (especially large or exotic species) due to its rapid onset, deep sedation, reversible effects, and relatively favorable safety profile compared to other protocols[1][3][7]. The mixture allows for effective short-term immobilization with smooth induction and recovery phases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine + butorphanol.